{"id":53879,"date":"2026-01-13T13:25:09","date_gmt":"2026-01-13T05:25:09","guid":{"rendered":"https:\/\/flcube.com\/?p=53879"},"modified":"2026-01-13T13:25:10","modified_gmt":"2026-01-13T05:25:10","slug":"carsgen-therapeutics-enters-phase-i-collaboration-with-dispatch-bio-for-ct053-car-t-in-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53879","title":{"rendered":"CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR\u2011T in Solid Tumors"},"content":{"rendered":"\n<p><strong>CARsgen Therapeutics Holdings Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2171:HKG\">HKG:\u202f2171<\/a>) announced a clinical collaboration with <strong>Dispatch Bio<\/strong> to evaluate <strong>DISP\u201111<\/strong>, a novel combination therapy comprising Dispatch\u2019s tumor\u2011specific oncolytic virus <strong>DV\u201110<\/strong> and CARsgen\u2019s <strong>CT053 (zevor\u2011cel)<\/strong> BCMA\u2011targeted CAR\u2011T cells, in a <strong>Phase I trial for epithelial\u2011derived solid tumors<\/strong> planned to initiate in China in H2\u202f2026.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-collaboration-milestone\">Collaboration Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partners<\/strong><\/td><td>CARsgen Therapeutics (HKEX:\u202f2171) &amp; Dispatch Bio (private)<\/td><\/tr><tr><td><strong>Therapy<\/strong><\/td><td>DISP\u201111 = DV\u201110 (Flare platform virus) + CT053 (BCMA CAR\u2011T)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Epithelial\u2011derived solid tumors<\/td><\/tr><tr><td><strong>Phase<\/strong><\/td><td>Phase I<\/td><\/tr><tr><td><strong>Location<\/strong><\/td><td>China<\/td><\/tr><tr><td><strong>Study Start<\/strong><\/td><td>H2\u202f2026 (planned)<\/td><\/tr><tr><td><strong>Patient Sequence<\/strong><\/td><td>DV\u201110 priming, followed by CT053 infusion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile\">Technology Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CT053 (Zevor\u2011cel):<\/strong> Autologous BCMA\u2011targeted CAR\u2011T, conditionally approved in China (Feb\u202f2024) for r\/r multiple myeloma; holds US FDA RMAT and Orphan Drug designations (2019)<\/li>\n\n\n\n<li><strong>DV\u201110:<\/strong> Tumor\u2011specific oncolytic virus derived from Dispatch Bio\u2019s proprietary <strong>Flare platform<\/strong>, engineered to selectively replicate in epithelial solid tumor cells and remodel the tumor microenvironment<\/li>\n\n\n\n<li><strong>Mechanistic Rationale:<\/strong> Preclinical data suggest DV\u201110 priming may upregulate BCMA expression on solid tumor cells and enhance CAR\u2011T infiltration\u2014a novel strategy to extend BCMA CAR\u2011T utility beyond hematologic malignancies<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> CARsgen\u2019s Shanghai GMP facility (200L capacity) will produce CT053; Dispatch Bio will supply DV\u201110 from its US cGMP site pending import approval<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-preclinical-evidence\">Preclinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Model<\/th><th>DV\u201110 Monotherapy<\/th><th>DV\u201110 + CT053 Combo<\/th><\/tr><\/thead><tbody><tr><td><strong>NSCLC PDX (n=12)<\/strong><\/td><td>12\u202f% tumor regression<\/td><td>68\u202f% tumor regression<\/td><\/tr><tr><td><strong>CRC PDX (n=10)<\/strong><\/td><td>8\u202f% tumor regression<\/td><td>55\u202f% tumor regression<\/td><\/tr><tr><td><strong>BCMA Upregulation<\/strong><\/td><td>2.3\u2011fold increase<\/td><td>4.1\u2011fold increase<\/td><\/tr><tr><td><strong>CAR\u2011T Infiltration<\/strong><\/td><td>Baseline<\/td><td>3.5\u2011fold increase<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Mouse studies demonstrated <strong>no additive toxicity<\/strong> with sequential dosing; virus cleared within 14\u202fdays pre\u2011CAR\u2011T infusion.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-revenue-forecast\">Market Opportunity &amp; Revenue Forecast<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>China Epithelial Solid Tumor Incidence<\/strong><\/td><td>3,200,000<\/td><td>3,300,000<\/td><td>3,400,000<\/td><\/tr><tr><td><strong>Eligible for Experimental Therapy<\/strong><\/td><td>480,000<\/td><td>495,000<\/td><td>510,000<\/td><\/tr><tr><td><strong>CT053 Solid Tumor Market Share Target<\/strong><\/td><td>0\u202f%<\/td><td>0.5\u202f%<\/td><td>1.2\u202f%<\/td><\/tr><tr><td><strong>Estimated Annual Price (\u00a5)<\/strong><\/td><td>\u2013<\/td><td>\u00a5280,000<\/td><td>\u00a5265,000<\/td><\/tr><tr><td><strong>China Revenue Forecast<\/strong><\/td><td>\u2013<\/td><td>\u00a5672\u202fmillion<\/td><td>\u00a51.62\u202fbillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Strategic Value:<\/strong> Expands CT053 beyond myeloma into <strong>\u00a585\u202fbillion<\/strong> China solid tumor market; successful POC would trigger <strong>global Phase II<\/strong> and partnership expansion<\/li>\n\n\n\n<li><strong>Deal Structure:<\/strong> Co\u2011development agreement with <strong>profit\u2011sharing in China<\/strong>; Dispatch Bio retains <strong>US\/EU rights<\/strong> with milestone payments to CARsgen upon IND approval<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong><\/li>\n\n\n\n<li><strong>Legend Biotech<\/strong> (BCMA CAR\u2011T) and <strong>JW Therapeutics<\/strong> focus on hematology; no BCMA CAR\u2011T in solid tumors<\/li>\n\n\n\n<li><strong>Oncolytic virus combos:<\/strong> <strong>Candel Therapeutics<\/strong> and <strong>Hookipa<\/strong> in early\u2011stage solid tumor trials, but none paired with CAR\u2011T<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical trial initiation, preclinical to clinical translation, and revenue potential for CT053 in solid tumors. Actual results may differ due to regulatory approvals, patient enrollment, and unforeseen toxicities.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CARsgen Therapeutics Holdings Ltd (HKG:\u202f2171) announced a clinical collaboration with Dispatch Bio to evaluate DISP\u201111,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":53881,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,21,379,77,29,4549,1188],"class_list":["post-53879","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-car-t","tag-carsgen-therapeutics","tag-cell-therapy","tag-combination-therapy","tag-dispatch-bio","tag-hkg-2171"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR\u2011T in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CARsgen Therapeutics Holdings Ltd (HKG:\u202f2171) announced a clinical collaboration with Dispatch Bio to evaluate DISP\u201111, a novel combination therapy comprising Dispatch\u2019s tumor\u2011specific oncolytic virus DV\u201110 and CARsgen\u2019s CT053 (zevor\u2011cel) BCMA\u2011targeted CAR\u2011T cells, in a Phase I trial for epithelial\u2011derived solid tumors planned to initiate in China in H2\u202f2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53879\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR\u2011T in Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"CARsgen Therapeutics Holdings Ltd (HKG:\u202f2171) announced a clinical collaboration with Dispatch Bio to evaluate DISP\u201111, a novel combination therapy comprising Dispatch\u2019s tumor\u2011specific oncolytic virus DV\u201110 and CARsgen\u2019s CT053 (zevor\u2011cel) BCMA\u2011targeted CAR\u2011T cells, in a Phase I trial for epithelial\u2011derived solid tumors planned to initiate in China in H2\u202f2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53879\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-13T05:25:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-13T05:25:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1301.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53879#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53879\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR\u2011T in Solid Tumors\",\"datePublished\":\"2026-01-13T05:25:09+00:00\",\"dateModified\":\"2026-01-13T05:25:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53879\"},\"wordCount\":436,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53879#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1301.webp\",\"keywords\":[\"Cancer\",\"CAR-T\",\"CARsgen Therapeutics\",\"Cell-therapy\",\"Combination therapy\",\"Dispatch Bio\",\"HKG: 2171\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53879#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53879\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53879\",\"name\":\"CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR\u2011T in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53879#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53879#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1301.webp\",\"datePublished\":\"2026-01-13T05:25:09+00:00\",\"dateModified\":\"2026-01-13T05:25:10+00:00\",\"description\":\"CARsgen Therapeutics Holdings Ltd (HKG:\u202f2171) announced a clinical collaboration with Dispatch Bio to evaluate DISP\u201111, a novel combination therapy comprising Dispatch\u2019s tumor\u2011specific oncolytic virus DV\u201110 and CARsgen\u2019s CT053 (zevor\u2011cel) BCMA\u2011targeted CAR\u2011T cells, in a Phase I trial for epithelial\u2011derived solid tumors planned to initiate in China in H2\u202f2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53879#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53879\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53879#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1301.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/1301.webp\",\"width\":1080,\"height\":608,\"caption\":\"CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR\u2011T in Solid Tumors\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53879#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR\u2011T in Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR\u2011T in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"CARsgen Therapeutics Holdings Ltd (HKG:\u202f2171) announced a clinical collaboration with Dispatch Bio to evaluate DISP\u201111, a novel combination therapy comprising Dispatch\u2019s tumor\u2011specific oncolytic virus DV\u201110 and CARsgen\u2019s CT053 (zevor\u2011cel) BCMA\u2011targeted CAR\u2011T cells, in a Phase I trial for epithelial\u2011derived solid tumors planned to initiate in China in H2\u202f2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53879","og_locale":"en_US","og_type":"article","og_title":"CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR\u2011T in Solid Tumors","og_description":"CARsgen Therapeutics Holdings Ltd (HKG:\u202f2171) announced a clinical collaboration with Dispatch Bio to evaluate DISP\u201111, a novel combination therapy comprising Dispatch\u2019s tumor\u2011specific oncolytic virus DV\u201110 and CARsgen\u2019s CT053 (zevor\u2011cel) BCMA\u2011targeted CAR\u2011T cells, in a Phase I trial for epithelial\u2011derived solid tumors planned to initiate in China in H2\u202f2026.","og_url":"https:\/\/flcube.com\/?p=53879","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-13T05:25:09+00:00","article_modified_time":"2026-01-13T05:25:10+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1301.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53879#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53879"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR\u2011T in Solid Tumors","datePublished":"2026-01-13T05:25:09+00:00","dateModified":"2026-01-13T05:25:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53879"},"wordCount":436,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=53879#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1301.webp","keywords":["Cancer","CAR-T","CARsgen Therapeutics","Cell-therapy","Combination therapy","Dispatch Bio","HKG: 2171"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53879#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53879","url":"https:\/\/flcube.com\/?p=53879","name":"CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR\u2011T in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=53879#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=53879#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1301.webp","datePublished":"2026-01-13T05:25:09+00:00","dateModified":"2026-01-13T05:25:10+00:00","description":"CARsgen Therapeutics Holdings Ltd (HKG:\u202f2171) announced a clinical collaboration with Dispatch Bio to evaluate DISP\u201111, a novel combination therapy comprising Dispatch\u2019s tumor\u2011specific oncolytic virus DV\u201110 and CARsgen\u2019s CT053 (zevor\u2011cel) BCMA\u2011targeted CAR\u2011T cells, in a Phase I trial for epithelial\u2011derived solid tumors planned to initiate in China in H2\u202f2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53879#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53879"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=53879#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1301.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1301.webp","width":1080,"height":608,"caption":"CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR\u2011T in Solid Tumors"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53879#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR\u2011T in Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/1301.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53879"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53879\/revisions"}],"predecessor-version":[{"id":53882,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53879\/revisions\/53882"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/53881"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53879"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53879"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}